BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company
- 27 Mar 2018 Planned primary completion date changed from 28 May 2018 to 3 Aug 2018.
- 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the company expects this study to complete in the fourth quarter of 2018.
- 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the company expects topline results from this phase 3 trial with rimegepant Zydis ODT in the fourth quarter of 2018.